Study to establish appropriate protocols for cholangiocarcinoma in Dynamic-CT

Study to establish appropriate protocols for cholangiocarcinoma in Dynamic-CT - Study to establish appropriate protocols for cholangiocarcinoma in Dynamic-CT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052646

Enrollment

100

Registered

2023-10-30

Start date

2022-09-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

extrahepatic cholangiocarcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who underwent surgery at Iwate Medical University Hospital or affiliated Uchimaru MC between January 1, 2011 and December 31, 2021, and had a pathologically confirmed diagnosis of cholangiocarcinoma. Cases in which CT was taken before treatment (bile duct stent, surgical resection, chemotherapy). Patients diagnosed with cholangiocarcinoma by pathological examination, whether preoperative or postoperative. Patients must be at least 20 years of age. No gender restriction.

Exclusion criteria

Exclusion criteria: Cases in which CT was taken but no protocol was described, such as the timing of the CT. EHD cancer was not the clinical diagnosis. Cases with confirmed reduced renal function (eGFR < 45 mL/min/1.73 m2). Patients who refused to participate in the study by opting out.

Design outcomes

Primary

Measure	Time frame
Primary site of cholangiocarcinoma (if in the hilar region, also evaluate the Bismuth classification) Evaluation of horizontal extension in each imaging phase. Direction of horizontal extension (duodenal or hepatic). Evaluation of vascular invasion in each contrast-enhanced phase. Evaluation of adjacent organ invasion in each imaging phase (liver, pancreas, duodenum) Subjective assessment of contrast effect in each contrast phase(5-point scale). Objective assessment in each contrast phase(measurement of CT values). Measurement of scan delay ratio in each contrast phase.	—

Measure

Time frame

Primary site of cholangiocarcinoma (if in the hilar region, also evaluate the Bismuth classification) Evaluation of horizontal extension in each imaging phase. Direction of horizontal extension (duodenal or hepatic). Evaluation of vascular invasion in each contrast-enhanced phase. Evaluation of adjacent organ invasion in each imaging phase (liver, pancreas, duodenum) Subjective assessment of contrast effect in each contrast phase(5-point scale). Objective assessment in each contrast phase(measurement of CT values). Measurement of scan delay ratio in each contrast phase.

—

Countries

Japan

Contacts

Public ContactEisuke Mukaida

Iwate Medical University School of Medicine. Department of Radiology

mukaida@iwate-med.ac.jp019-613-7111

Outcome results